JP7206132B2 - メチルラクタム環化合物及びその医薬用途 - Google Patents

メチルラクタム環化合物及びその医薬用途 Download PDF

Info

Publication number
JP7206132B2
JP7206132B2 JP2019035140A JP2019035140A JP7206132B2 JP 7206132 B2 JP7206132 B2 JP 7206132B2 JP 2019035140 A JP2019035140 A JP 2019035140A JP 2019035140 A JP2019035140 A JP 2019035140A JP 7206132 B2 JP7206132 B2 JP 7206132B2
Authority
JP
Japan
Prior art keywords
compound
acid
formula
reaction mixture
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019035140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019151627A5 (enExample
JP2019151627A (ja
Inventor
智也 三浦
義憲 玉谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of JP2019151627A publication Critical patent/JP2019151627A/ja
Publication of JP2019151627A5 publication Critical patent/JP2019151627A5/ja
Priority to JP2023000037A priority Critical patent/JP2023026566A/ja
Application granted granted Critical
Publication of JP7206132B2 publication Critical patent/JP7206132B2/ja
Priority to JP2024214451A priority patent/JP2025026615A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019035140A 2018-03-01 2019-02-28 メチルラクタム環化合物及びその医薬用途 Active JP7206132B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023000037A JP2023026566A (ja) 2018-03-01 2023-01-04 メチルラクタム環化合物及びその医薬用途
JP2024214451A JP2025026615A (ja) 2018-03-01 2024-12-09 メチルラクタム環化合物及びその医薬用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018036307 2018-03-01
JP2018036307 2018-03-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023000037A Division JP2023026566A (ja) 2018-03-01 2023-01-04 メチルラクタム環化合物及びその医薬用途

Publications (3)

Publication Number Publication Date
JP2019151627A JP2019151627A (ja) 2019-09-12
JP2019151627A5 JP2019151627A5 (enExample) 2022-03-07
JP7206132B2 true JP7206132B2 (ja) 2023-01-17

Family

ID=67806229

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019035140A Active JP7206132B2 (ja) 2018-03-01 2019-02-28 メチルラクタム環化合物及びその医薬用途
JP2023000037A Pending JP2023026566A (ja) 2018-03-01 2023-01-04 メチルラクタム環化合物及びその医薬用途
JP2024214451A Pending JP2025026615A (ja) 2018-03-01 2024-12-09 メチルラクタム環化合物及びその医薬用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023000037A Pending JP2023026566A (ja) 2018-03-01 2023-01-04 メチルラクタム環化合物及びその医薬用途
JP2024214451A Pending JP2025026615A (ja) 2018-03-01 2024-12-09 メチルラクタム環化合物及びその医薬用途

Country Status (21)

Country Link
US (3) US11014910B2 (enExample)
EP (1) EP3760624A4 (enExample)
JP (3) JP7206132B2 (enExample)
KR (1) KR102795351B1 (enExample)
CN (1) CN111757877B (enExample)
AR (1) AR114418A1 (enExample)
AU (1) AU2019227770B2 (enExample)
BR (1) BR112020016788A2 (enExample)
CA (1) CA3087859A1 (enExample)
CL (1) CL2020002199A1 (enExample)
IL (1) IL276311B2 (enExample)
MA (1) MA52427A (enExample)
MX (1) MX2020009070A (enExample)
MY (1) MY205197A (enExample)
PE (1) PE20210123A1 (enExample)
PH (1) PH12020551340A1 (enExample)
SA (1) SA520420037B1 (enExample)
SG (1) SG11202007120UA (enExample)
TW (1) TWI805699B (enExample)
WO (1) WO2019168096A1 (enExample)
ZA (1) ZA202004600B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021045159A1 (enExample) * 2019-09-04 2021-03-11
JP2023026566A (ja) * 2018-03-01 2023-02-24 日本たばこ産業株式会社 メチルラクタム環化合物及びその医薬用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111902408B (zh) 2018-04-04 2023-11-14 日本烟草产业株式会社 杂芳基取代的吡唑化合物及其药物用途
JPWO2021187548A1 (enExample) * 2020-03-19 2021-09-23

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
JP2007332034A (ja) 2005-06-08 2007-12-27 Japan Tobacco Inc 複素環化合物
JP2009534439A (ja) 2006-04-27 2009-09-24 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂｘカンナビノイド受容体モジュレータ及びカリウムチャンネルモジュレータを含む医薬組成物
JP2010523583A (ja) 2007-04-02 2010-07-15 セラコス・インコーポレイテッド ベンジルグルコシド誘導体およびその用途
WO2013031922A1 (ja) 2011-08-31 2013-03-07 日本たばこ産業株式会社 ピラゾール化合物及びその医薬用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657282A (en) * 1969-01-23 1972-04-18 Merck & Co Inc Carboxyepoxyethyl-1-phosphonic acid and derivatives
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2515119A1 (en) 2003-02-07 2004-08-19 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
CN1980665A (zh) 2004-07-07 2007-06-13 默克公司 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法
EP1811983B1 (en) 2004-11-16 2020-10-07 GW Pharma Limited New use for cannabinoid
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
CN101243074A (zh) * 2005-06-08 2008-08-13 日本烟草产业株式会社 杂环化合物
WO2006132436A1 (ja) 2005-06-08 2006-12-14 Japan Tobacco Inc. 複素環化合物
JP2009523748A (ja) 2006-01-18 2009-06-25 シエナ ビオテク ソシエタ ペル アチオニ α７ニコチン性アセチルコリン受容体の調節物質およびそれらの治療への使用
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
KR101450356B1 (ko) 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
WO2008061796A2 (en) 2006-11-24 2008-05-29 Ac Immune Sa Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
US20090181952A1 (en) 2008-01-14 2009-07-16 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
TW201006832A (en) 2008-07-15 2010-02-16 Novartis Ag Organic compounds
RU2017144535A (ru) 2010-03-30 2019-02-18 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
CN111902408B (zh) 2018-04-04 2023-11-14 日本烟草产业株式会社 杂芳基取代的吡唑化合物及其药物用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007332034A (ja) 2005-06-08 2007-12-27 Japan Tobacco Inc 複素環化合物
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
JP2009534439A (ja) 2006-04-27 2009-09-24 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂｘカンナビノイド受容体モジュレータ及びカリウムチャンネルモジュレータを含む医薬組成物
JP2010523583A (ja) 2007-04-02 2010-07-15 セラコス・インコーポレイテッド ベンジルグルコシド誘導体およびその用途
WO2013031922A1 (ja) 2011-08-31 2013-03-07 日本たばこ産業株式会社 ピラゾール化合物及びその医薬用途

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023026566A (ja) * 2018-03-01 2023-02-24 日本たばこ産業株式会社 メチルラクタム環化合物及びその医薬用途
JPWO2021045159A1 (enExample) * 2019-09-04 2021-03-11
JP7692832B2 (ja) 2019-09-04 2025-06-16 日本たばこ産業株式会社 併用医薬による糖尿病の治療又は予防方法

Also Published As

Publication number Publication date
AU2019227770A1 (en) 2020-07-09
US20190352284A1 (en) 2019-11-21
TWI805699B (zh) 2023-06-21
SG11202007120UA (en) 2020-08-28
ZA202004600B (en) 2022-03-30
CN111757877B (zh) 2023-10-27
MX2020009070A (es) 2020-10-08
AU2019227770B2 (en) 2023-10-05
JP2023026566A (ja) 2023-02-24
US20240174646A1 (en) 2024-05-30
MY205197A (en) 2024-10-07
IL276311A (en) 2020-09-30
SA520420037B1 (ar) 2024-07-28
MA52427A (fr) 2021-01-06
IL276311B1 (en) 2023-06-01
US20220064148A1 (en) 2022-03-03
KR20200128033A (ko) 2020-11-11
PE20210123A1 (es) 2021-01-19
EP3760624A4 (en) 2021-11-03
CA3087859A1 (en) 2019-09-06
KR102795351B1 (ko) 2025-04-16
CN111757877A (zh) 2020-10-09
WO2019168096A1 (ja) 2019-09-06
PH12020551340A1 (en) 2021-05-31
BR112020016788A2 (pt) 2021-01-12
CL2020002199A1 (es) 2020-12-18
RU2020131756A (ru) 2022-03-28
IL276311B2 (en) 2023-10-01
EP3760624A1 (en) 2021-01-06
AR114418A1 (es) 2020-09-02
US11014910B2 (en) 2021-05-25
JP2019151627A (ja) 2019-09-12
TW202000660A (zh) 2020-01-01
JP2025026615A (ja) 2025-02-21

Similar Documents

Publication Publication Date Title
JP2023026566A (ja) メチルラクタム環化合物及びその医薬用途
KR101991326B1 (ko) 오피오이드 수용체 리간드와 그 용도 및 제조방법
JP7130588B2 (ja) ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
JP2025094217A (ja) 併用医薬による糖尿病の治療又は予防方法
JP2025138791A (ja) 慢性腎臓病の治療又は予防方法
RU2809634C2 (ru) Соединение с метиллактамным кольцом и его применение в фармацевтике
HK40044833A (en) Methyllactam ring compound and medicinal use thereof
HK40067960A (en) Therapeutic or prophylactic method for diabetes using combination medicine
WO2025137342A2 (en) 5-carboxamido and 5-carboxyalkyl phenethylamines
HK40068410A (en) Chronic kidney disease treatment or prevention method

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220927

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230104

R150 Certificate of patent or registration of utility model

Ref document number: 7206132

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150